No Data
No Data
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $15
$HUMA Stock Is up 7% Today. Here's What We See in Our Data.
Benchmark Co. Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $17
Express News | Humacyte Issued US Patent Covering Manufacturing Of Symvess And Other Bioengineered Tissues
Analysts Offer Insights on Healthcare Companies: Andlauer Healthcare Group (OtherANDHF) and Humacyte (HUMA)
Humacyte to Present at the TD Cowen 45th Annual Health Care Conference